Holen Sie sich die Stockscreener-App
28.75
1.66%
0.47
Handel nachbörslich:
28.75
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - GlobeNewswire Inc.
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat
Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha
Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World
Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat
Expert Ratings For Dianthus Therapeutics - Benzinga
Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Great Point Partners LLC Boosts Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Rhumbline Advisers Acquires Shares of 32,138 Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dropbox CEO Andrew Houston sells shares worth over $87,000 - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2% - MarketBeat
How does Dianthus Therapeutics Inc (DNTH) change from a tortoise to a hare? - SETE News
Dyne Therapeutics’ (DYN) “Overweight” Rating Reaffirmed at Piper Sandler - Defense World
Incyte Insiders Sold US$4.8m Of Shares Suggesting Hesitancy - Simply Wall St
Victory Capital Management Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.5% - Defense World
31,047 Shares in Incyte Co. (NASDAQ:INCY) Purchased by XTX Topco Ltd - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.5% Higher - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.3% - Defense World
WINTON GROUP Ltd Buys Shares of 10,238 Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
Dyne Therapeutics director sells over $161k in company stock - Investing.com India
Dyne Therapeutics Inc (DYN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Decreases By 6.9% - MarketBeat
Bank of New York Mellon Corp Increases Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Bank of New York Mellon Corp Has $2.10 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Rhumbline Advisers Raises Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dianthus Therapeutics appoints new board member - Investing.com India
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3% - MarketBeat
Ginkgo Bioworks executive sells over $7,000 in stock - Investing.com India
Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Sell at StockNews.com - MarketBeat
Dianthus Therapeutics Appoints Steven Romano to Board - TipRanks
Atlas Venture Life Science Advisors LLC Lowers Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):